Biotech Values

[rfj1862]

>You specifically stated in 2 posts that JAV's pps isn't going anywhere due to UK approval, and 2. they won't make any money in the EU with Dyloject.<

Agree with Thomas. Dyloject is perhaps the world's easiest sell in the context of a heavily regulated, cost-sensitive market.

The key to selling in such an environment is to demonstrate value. The ability to skip the pharmacy and go straight to the patient is huge, as is the ability to cut down on bed time and personnel costs associated with infusion.

These are all clear-cut advantages for anyone trying to save money. The fact that Dyloject is better tolerated and perhaps slightly more efficacious than current options in Europe is just dressing. Nice to have, but not critical for penny-pinchers.

DrBio's posts on JAV have been ridiculous.